Reimagining

Discovery

We are a groundbreaking immunotherapy venture studio. We accelerate early-stage R&D discovery and build drug discovery programs to create companies that cure diseases from COVID to Cancer.

Arrow down

Reimagining

discovery

We are a groundbreaking immunotherapy venture studio. We accelerate early stage R/D discovery and build programs and companies, to cure diseases from COVID to Cancer.

Arrow down

Immunotherapy with Impact

Our studio of experienced, immunology-focused drug developers maximizes value creation by forming multiple, thematically aligned startups to develop and commercialize immunotherapeutics. We partner with university-based collaborators to extend novel and untapped fundamental biological observations, create proof-of-concept data, and generate advanced development candidate packages using our expertise and internal laboratories.

Bridging the “Therapeutic Valley of Death”

Novel immunotherapeutics face a formidable therapeutic valley of death. Successfully navigating this valley provides tremendous value to patients and investors – typically the largest step-up in a program’s lifetime.  We provide the neccessary R&D infrastructure to rapidly and effectively traverse this valley.

Foundery Innovations. Engineering Success. Validated efficacy. Validated safety. Validated developability.The valley of death. Poor success rate of novel observations and targets traversing to clinical assessment.Observation. Novel observation or target identification with potential therapeutic value. Limited valuation.Clinical drug 
development candidate. NewCo formation, 
or out-licensing. Large Step-up 
in valuation.Foundery Innovations. Engineering Success. Validated efficacy. Validated safety. Validated developability.

Our Founders

Our studio was forged in 2021 by – Max, Michel, and Sriram – united by their shared goal to re-establish discovery as the basis for the next generation of immunotherapies.

With their deep knowledge of immunobiology and their impressive track record of discovering and developing multiple, multibillion-dollar immunotherapies, they have positioned Foundery to increase the efficiency and effectiveness of the pre-clinical R&D process.

They aim to preserve the innovative culture of biotech and bridge the translational gap by providing leading academic scientists with exclusive access to best-in-class technology platforms and the necessary R&D infrastructure to transform their discoveries into breakthrough therapies.

Photo of Max Krummel

Matthew “Max” Krummel, Ph.D.

  • Discovered and patented Checkpoint blockade therapy, anti-CTLA-4, in 1995, which had more than $2B in Sales
  • Founded Pionyr, anti-TREM1/2, in 2016, which resulted in a $1.7B deal with Gilead
  • Discovered Immune Archetypes in Cancer and COVID
  • Professor at UCSF since 2001; Robert E. Smith Endowed Chair in Experimental Pathology; Chair of the ImmunoX Initiative
View full bio
Michel Streuli, Ph.D.

Michel Streuli, Ph.D.

  • Drove early development of multiple immunotherapies, including IntronA and Keytruda, which resulted in combined sales of more than $14B
  • 20 years of industry experience across Organon, Schering-Plough, Merck, Gilead, and Pionyr
  • 10 years of academic experience including professorships at Harvard Medical School and Dana-Farber Cancer Institute faculty
View full bio
Sriram

Venkataraman “Sriram”, Ph.D.

  • Guided pre-clinical pharmacology for Keytruda
  • Led Pionyr's non-clinical program for PY314
  • More than 15 years of experience in immunology and immuno-oncology R&D as well as strategy development at Schering Plough, Merck, Gilead, and Pionyr
  • Expertise in small molecule and biologics development for immuno-oncology
View full bio

Contact Us

Interested in learning more? We're looking forward to hearing from you.

GET IN TOUCH
Foundery Innovations